CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial.

Abstract

The rate of long-term remissions after treatment of peripheral T cell lymphomas (PTCL) with standard CHOP-like protocols is unsatisfactory. A prospective multicenter phase II trial was initiated in untreated patients with PTCL of all International Prognostic Index-risk groups, evaluating alemtuzumab consolidation in patients with complete or good partial remission after CHO(E)P-14 induction. Twenty-nine (70.7 %) of the 41 enrolled patients received alemtuzumab consolidation (133 mg in total). The main grades 3-4 toxicities during alemtuzumab therapy were infections and neutropenia with one potentially treatment-related death. Complete responses were seen in 58.5 %, partial responses in 2.4 % and 29.3 % had progressive disease. After a median observation time of 46 months, 19 patients have died, 16 of them due to lymphoma and/or salvage therapy complications. Event-free and overall survival at 3 years in the whole intent to treat population are 32.3 and 62.5 %, respectively, and 42.4 and 75.1 % in the patients who received alemtuzumab. In conclusion, application of a short course of alemtuzumab after CHO(E)P-14 induction is feasible although complicated by severe infections. A current phase III trial, applying alemtuzumab as part of the initial chemotherapy protocol to avoid early progression, will further clarify its significance for the therapeutic outcome.

• Authors: C Binder, M Ziepert, M Pfreundschuh, U Dührsen, H Eimermacher, A Aldaoud, A Rosenwald, M Loeffler, N Schmitz, L Truemper, German High Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)
• Journal: Annals of hematology (Ann Hematol) Vol. 92 Issue 11 Pg. 1521-8 (Nov 2013) ISSN: 1432-0584 [Electronic] Germany
• PMID: 23978945 (Publication Type: Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Humanized
• Antineoplastic Agents
• Alemtuzumab
• Vincristine
• Doxorubicin
• Cyclophosphamide
• Prednisone

Topics

• Adult
• Aged
• Alemtuzumab
• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Agents (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage)
• Cohort Studies
• Cyclophosphamide (administration & dosage)
• Disease Progression
• Doxorubicin (administration & dosage)
• Drug Administration Schedule
• Female
• Follow-Up Studies
• Humans
• Lymphoma, T-Cell, Peripheral (mortality, pathology, therapy)
• Male
• Middle Aged
• Prednisone (administration & dosage)
• Prospective Studies
• Survival Rate (trends)
• Treatment Outcome
• Vincristine (administration & dosage)
• Young Adult